Ligand Based CoMFA, CoMSIA and HQSAR Analysis of CCR5 Antagonists

  • Gadhe, Changdev G. (Department of Bio-New Drug Development, College of Medicine, Chosun University) ;
  • Lee, Sung-Haeng (Department of Bio-New Drug Development, College of Medicine, Chosun University) ;
  • Madhavan, Thirumurthy (Department of Bio-New Drug Development, College of Medicine, Chosun University) ;
  • Kothandan, Gugan (Department of Bio-New Drug Development, College of Medicine, Chosun University) ;
  • Choi, Du-Bok (Biotechnology Lab, BK Company R&D Center) ;
  • Cho, Seung-Joo (Department of Bio-New Drug Development, College of Medicine, Chosun University)
  • Received : 2010.06.24
  • Accepted : 2010.08.19
  • Published : 2010.10.20


In this study, we have developed QSAR models for a series of 38 piperidine-4-carboxamide CCR5 antagonists using CoMFA, CoMSIA and HQSAR methods. Developed models showed good statistics in terms of $q^2$ and $r^2$ values. Best predictions obtained with standard CoMFA model ($r^2$ = 0.888, $q^2$ = 0.651) and combined CoMSIA model ($r^2$ = 0.892, $q^2$ = 0.665) with electrostatics and H-bond acceptor parameter. The validity of developed models was assessed by test set of 9 compounds, which showed good predictive correlation coefficient for CoMFA (0.804) and CoMSIA (0.844). Bootstrapped analysis showed statistically significant and robust CoMFA (0.968) and CoMSIA (0.936) models. Best HQSAR model was obtained with a $q^2$ of 0.662 and $r^2$ of 0.936 using atom, connection, hydrogen, donor and acceptor as parameters and fragment size (7-10) with optimum number of 6 components. Predictive power of developed HQSAR model was proved by test set and it was found to be 0.728.



Supported by : National Research Foundation of Korea (NRF)


  1. Chermann, J. C.; Barre-Sinoussi, F.; Dauguet, C.; Brun-Vezinet, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Antibiot. Chemother. 1983, 32, 48.
  2. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C. Antimicrob. Agents Chemother. 2005, 49, 4721.
  3. Furtado, M. R.; Callaway, D. S.; Phair, J. P.; Kunstman, K. J.; Stanton, J. L.; Macken, C. A.; Perelson, A. S.; Wolinsky, S. M. New Engl. J. Med. 1999, 340, 1614.
  4. Coffin, J.; Haase, A.; Levy, J. A.; Montagnier, L.; Oroszlan, S.; Teich, N.; Temin, H.; Toyoshima, K.; Varmus, H.; Vogt, P. Nature 1986, 321, 10.
  5. Koot, M.; van’t Wout, A. B.; Kootstra, N. A.; Goede, R. E.; Tersmette, M.; Schuitemaker, H. J. Infect. Dis. 1996, 173, 349.
  6. Fackler, O. T.; Peterlin, B. M. Curr. Biol. 2000, 10, 1005.
  7. Piot, P.; Bartos, M.; Ghys, P. D.; Walker, N.; Schwartlander, B. Nature 2001, 410, 968.
  8. Strader, C. D.; Fong, T. M.; Tota, M. R.; Underwood, D.; Dixon, R. A. F. Annu. Rev. Biochem. 1994, 63, 101.
  9. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Arya, S. K.; Gallo, R. C.; Lusso, P. Science 1995, 270, 1811.
  10. Cocchi, F.; DeVico, A. L.; Garzino-Demo, A.; Lusso, P.; Gallo, R. C. Science 1996, 274, 1393.
  11. Alkhatib, G.; Combadiere, C.; Broder, C. C.; Feng, Y.; Kennedy, P. E.; Murphy, P. M.; Berger, E. A. Science 1996, 272, 1955.
  12. Li, G.; Haney, K. M.; Kellogg, G. E.; Zhang, Y. J. Chem. Inf. Model. 2009, 49, 120.
  13. Strizki, J. M.; Xu, S.; Wagner, N. E.; Wojcik, L.; Liu, J.; Hou, Y.; Endres, M.; Palani, A.; Shapiro, S.; Clader, J. W. Proc. Nat. Acad. Sci. USA 2001, 98, 12718.
  14. Tagat, J. R.; McCombie, S. W.; Nazareno, D.; Labroli, M. A.; Xiao, Y.; Steensma, R. W.; Strizki, J. M.; Baroudy, B. M.; Cox, K.; Lachowicz, J. J. Med. Chem. 2004, 47, 2405.
  15. Strizki, J. M.; Tremblay, C.; Xu, S.; Wojcik, L.; Wagner, N.; Gonsiorek, W.; Hipkin, R. W.; Chou, C. C.; Pugliese-Sivo, C.; Xiao Y. Antimicrob. Agents Chemother. 2005, 49, 4911.
  16. Maeda, K.; Nakata, H.; Koh, Y.; Miyakawa, T.; Ogata, H.; Takaoka, Y.; Shibayama, S.; Sagawa, K.; Fukushima, D.; Moravek, J. J. Virol. 2004, 78, 8654.
  17. Nichols, W. G.; Steel, H. M.; Bonny, T.; Adkison, K.; Curtis, L.; Millard, J.; Kabeya, K.; Clumeck, N. Antimicrob. Agents Chemother. 2008, 52, 858.
  18. Aher, Y. D.; Agrawal, A.; Bharatam, P. V.; Garg, P. J. Mol. Model. 2007, 13, 519.
  19. Afantitis, A.; Melagraki, G.; Sarimveis, H.; Koutentis, P. A.; Markopoulos, J.; Igglessi-Markopoulou, O. J. Comput.-Aided Mol. Des. 2006, 20, 83.
  20. Song, M.; Breneman, C. M.; Sukumar, N. Bioorg. Med. Chem. 2004, 12, 489.
  21. Zhuo, Y.; Kong, R.; Cong, X.; Chen, W.; Wang, C. Eur. J. Med. Chem. 2008, 43, 2724.
  22. Xu, Y.; Liu, H.; Niu, C.; Luo, C.; Luo, X.; Shen, J.; Chen, K.; Jiang, H. Bioorg. Med. Chem. 2004, 12, 6193.
  23. Imamura, S.; Nishikawa, Y.; Ichikawa, T.; Hattori, T.; Matsushita, Y.; Hashiguchi, S.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Sugihara, Y. Bioorg. Med. Chem. 2005, 13, 397.
  24. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988, 110, 5959.
  25. Klebe, G.; Abraham, U.; Mietzner, T. J. Med. Chem. 1994, 37, 4130.
  26. Hurst T, Heritage T. 213th ACS Natl. Meeting, San Francisco, CA, 1997, CINF 019.
  27. S. H. R. SYBYL8.1; Tripos Inc., St. Louis, MO 63144 USA.
  28. Ash, S.; Cline, M. A.; Homer, R. W.; Hurst, T.; Smith, G. B. J. Chem. Inf. Comput. Sci. 1997, 37, 71.
  29. Dunn, W. J.; Wold, S.; Edlund, V.; Hellherg, S.; Gasteiger, J. Quant. Struct.-Act. Relat. 1984, 3, 131.
  30. Wold, S.; Sjostrom, M.; Eriksson, L. Chemom. Intell. Lab. Syst. 2001, 58, 109.
  31. Cramer, R. D. Perspect. Drug Discovery Des. 1993, 1, 269.

Cited by

  1. Structural Insights from Binding Poses of CCR2 and CCR5 with Clinically Important Antagonists: A Combined In Silico Study vol.7, pp.3, 2012,
  2. Enhancement of P-gylcoprotein modulators of arylmethylamine-phenyl derivatives: an integrative modeling approach vol.22, pp.5, 2013,
  3. Computational modeling of human coreceptor CCR5 antagonist as a HIV-1 entry inhibitor: using an integrated homology modeling, docking, and membrane molecular dynamics simulation analysis approach vol.31, pp.11, 2013,
  4. Investigation of the Binding Site of CCR2 using 4-Azetidinyl-1-aryl-cyclohexane Derivatives: A Membrane Modeling and Molecular Dynamics Study vol.34, pp.11, 2013,
  5. Characterization of Binding Mode of the Heterobiaryl gp120 Inhibitor in HIV-1 Entry: A Molecular Docking and Dynamics Simulation Study vol.34, pp.8, 2013,
  6. The nociceptin receptor (NOPR) and its interaction with clinically important agonist molecules: a membrane molecular dynamics simulation study vol.10, pp.12, 2014,
  7. Discovery of a potential lead compound for treating leprosy with dapsone resistance mutation in M. leprae folP1 vol.12, pp.7, 2016,